Sorry, you need to enable JavaScript to visit this website.

LTFU Data | TECVAYLI® (teclistamab-cqyv) HCP

MajesTEC-1 LONGER-TERM FOLLOW-UP ANALYSIS AT 23 MONTHS1,2

You are now viewing a subsequent follow-up analysis of the MajesTEC-1 trial. This information is not included in the current full Prescribing Information.

Response rates with 23 months of median follow-up

Deep response bar

Depth of response

46.4% ≥CR† was demonstrated in the MajesTEC-1 trial

Duration of response

21.6 months mDOR(95% CI,14.9-NE)

*ORR: sCR+CR+VGPR+PR.

†≥CR: sCR+CR.

§≥VGPR: sCR+CR+VGPR.

CI, confidence interval; CR, complete response; mDOR, median duration of response; ORR, overall response rate; PR, partial response; sCR, stringent complete response; VGPR, very good partial response.

References:

  1. Data on file. Janssen Biotech, Inc.
  2. van de Donk NWCJ, Moreau P, Garfall AL, et al. Long-term follow-up from MajesTEC-1 of teclistamab, a BCMA x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). Poster presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting; June 2–6, 2023; Chicago, IL.

Exclamation point within triangleReview the safety profile of TECVAYLI® Arrow icon

Email iconConnect with a Janssen Oncology representativeTalk with Us
Stacked books iconAccess resources to help patients receive TECVAYLI® Explore Resources